TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A One-Year, Randomized, Open-Label, Parallel-Arm, Phase 3 Long-Term Safety Trial, With Controlled Adjustment of Dose, of Multiple Doses of CG5503 PR and Oxycodone CR in Subjects With Chronic Pain
Brief Summary: The purpose of this study is to evaluate the safety profile of tapentadol (CG5503) PR at doses of 100 mg - 250 mg administered twice daily over a maximum one year period to patients with at least a 3-month history of low back pain, or pain caused by knee or hip osteoarthritis.


Options:
A: Arm Label: buprenorphine transdermal system; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Arm Label: codeine paracetamol tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Codeine paracetamol | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): buprenorphine transdermal system | Intervention Type: DRUG; Name: Codeine paracetamol; Assigned to Arm(s): codeine paracetamol tablets
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: celecoxib | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Oxycodone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C
C: Arm Label: Tapentadol (CG5503); Type: EXPERIMENTAL; Interventions: Drug: Tapentadol (CG5503) ER | Arm Label: Oxycodone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone CR | Intervention Type: DRUG; Name: Oxycodone CR; Assigned to Arm(s): Oxycodone | Intervention Type: DRUG; Name: Tapentadol (CG5503) ER; Assigned to Arm(s): Tapentadol (CG5503)
D: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Tapentadol IR (CG5503) | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Tapentadol IR (CG5503) | Arm Label: 003; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxycodone IR | Arm Label: 004; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 005; Type: EXPERIMENTAL; Interventions: Drug: Tapentadol ER (CG5503) | Arm Label: 006; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxycodone CR | Arm Label: 007; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: oxycodone CR; Assigned to Arm(s): 006 | Intervention Type: DRUG; Name: oxycodone IR; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Tapentadol ER (CG5503); Assigned to Arm(s): 005 | Intervention Type: DRUG; Name: Tapentadol IR (CG5503); Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Tapentadol IR (CG5503); Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 007

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentre, Randomised, Double-Blind, Double Dummy, Parallel Group, 104-week Study to Compare the Effect of the Salmeterol/Fluticasone Propionate Combination Product (SERETIDE*) 50/500mcg Delivered Twice Daily Via the DISKUS*/ACCUHALER* Inhaler With Tiotropium Bromide 18 mcg Delivered Once Daily Via the HandiHaler Inhalation Device on the Rate of Health Care Utilisation Exacerbations in Subjects With Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: This is a comparator study to assess the relative efficacy of the combination product fluticasone propionate/salmeterol 50/500 and tiotropium bromide on the rate of exacerbations of chronic obstructive pulmonary disease (COPD) over a two year study interval.


Options:
A: Arm Label: Triple therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide/formoterol and tiotropium | Arm Label: Combination therapy; Type: PLACEBO_COMPARATOR; Interventions: Drug: Budesonide/formoterol and placebo | Intervention Type: DRUG; Name: Budesonide/formoterol and tiotropium; Assigned to Arm(s): Triple therapy | Intervention Type: DRUG; Name: Budesonide/formoterol and placebo; Assigned to Arm(s): Combination therapy
B: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Tiotropium bromide 18mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluticasone propionate/ salmeterol combination 50/500mcg; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentre, Randomised, Double-Blind, Double Dummy, Parallel Group, 104-week Study to Compare the Effect of the Salmeterol/Fluticasone Propionate Combination Product (SERETIDE*) 50/500mcg Delivered Twice Daily Via the DISKUS*/ACCUHALER* Inhaler With Tiotropium Bromide 18 mcg Delivered Once Daily Via the HandiHaler Inhalation Device on the Rate of Health Care Utilisation Exacerbations in Subjects With Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: This is a comparator study to assess the relative efficacy of the combination product fluticasone propionate/salmeterol 50/500 and tiotropium bromide on the rate of exacerbations of chronic obstructive pulmonary disease (COPD) over a two year study interval.


Options:
A: Intervention Type: DRUG; Name: SPIRIVA; Assigned to Arm(s): N/A
B: Arm Label: MF/F MDI 400/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF MDI 400 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate MDI (MF MDI) | Arm Label: Formoterol MDI 10 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol MDI | Arm Label: Placebo MDI BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 400/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI); Assigned to Arm(s): MF MDI 400 mcg BID | Intervention Type: DRUG; Name: Formoterol MDI; Assigned to Arm(s): Formoterol MDI 10 mcg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo MDI BID
C: Intervention Type: DRUG; Name: Tiotropium bromide 18mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluticasone propionate/ salmeterol combination 50/500mcg; Assigned to Arm(s): N/A
D: Intervention Type: DEVICE; Name: Pulmonary function Testing; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tiotropium bromide; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentre, Randomised, Double-Blind, Double Dummy, Parallel Group, 104-week Study to Compare the Effect of the Salmeterol/Fluticasone Propionate Combination Product (SERETIDE*) 50/500mcg Delivered Twice Daily Via the DISKUS*/ACCUHALER* Inhaler With Tiotropium Bromide 18 mcg Delivered Once Daily Via the HandiHaler Inhalation Device on the Rate of Health Care Utilisation Exacerbations in Subjects With Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: This is a comparator study to assess the relative efficacy of the combination product fluticasone propionate/salmeterol 50/500 and tiotropium bromide on the rate of exacerbations of chronic obstructive pulmonary disease (COPD) over a two year study interval.


Options:
A: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Tiotropium bromide 18mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluticasone propionate/ salmeterol combination 50/500mcg; Assigned to Arm(s): N/A
C: Arm Label: Tiotropium + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium bromide, Drug: Placebo Salmeterol | Arm Label: Salmeterol + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol, Drug: Placebo Tiotropium | Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Salmeterol + Placebo | Intervention Type: DRUG; Name: Placebo Salmeterol; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Placebo Tiotropium; Assigned to Arm(s): Salmeterol + Placebo
D: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentre, Randomised, Double-Blind, Double Dummy, Parallel Group, 104-week Study to Compare the Effect of the Salmeterol/Fluticasone Propionate Combination Product (SERETIDE*) 50/500mcg Delivered Twice Daily Via the DISKUS*/ACCUHALER* Inhaler With Tiotropium Bromide 18 mcg Delivered Once Daily Via the HandiHaler Inhalation Device on the Rate of Health Care Utilisation Exacerbations in Subjects With Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: This is a comparator study to assess the relative efficacy of the combination product fluticasone propionate/salmeterol 50/500 and tiotropium bromide on the rate of exacerbations of chronic obstructive pulmonary disease (COPD) over a two year study interval.


Options:
A: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Tiotropium bromide 18mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluticasone propionate/ salmeterol combination 50/500mcg; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Budesonide/formoterol pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Budesonide pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A
D: Arm Label: Inhaled corticosteroid, Then placebo; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate, Drug: Placebo | Arm Label: Placebo control, Then inhaled corticosteroid; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fluticasone propionate, Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate; Assigned to Arm(s): Inhaled corticosteroid, Then placebo, Placebo control, Then inhaled corticosteroid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Inhaled corticosteroid, Then placebo, Placebo control, Then inhaled corticosteroid

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of the Nutritional Fatty Acids During Pregnancy and Lactation for Early Human Adipose Tissue Development
Brief Summary: Pregnant and lactating women receive n-3 fatty acids starting from week 15 of gestation until 4 months post-partum (pp) in comparison to a control group, who only gets information about adequately healthy nutrition during pregnancy and lactation.

The amount of fat in newborns is measured through skinfold thickness, ultrasound, and magnetic resonance imaging (MRI).

It is hypothesised that a reduction in arachidonic acid intake and an increase of n-3 LC PUFAs (long chain polyunsaturated fatty acids) via supplements containing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) could lead to less expansive fat tissue development in the first year of life.


Options:
A: Arm Label: Marinol; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Marinol D-40 | Arm Label: Nutrition counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Marinol D-40; Assigned to Arm(s): Marinol
B: Arm Label: Fish Oil; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Fish Oil | Arm Label: Sunflower oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Sunflower Oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish Oil; Assigned to Arm(s): Fish Oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Sunflower Oil; Assigned to Arm(s): Sunflower oil
C: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Nutrition | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Nutrition | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutrition; Assigned to Arm(s): Control, Intervention
D: Intervention Type: PROCEDURE; Name: Supplement of fatty acid (DHA and AA); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of the Nutritional Fatty Acids During Pregnancy and Lactation for Early Human Adipose Tissue Development
Brief Summary: Pregnant and lactating women receive n-3 fatty acids starting from week 15 of gestation until 4 months post-partum (pp) in comparison to a control group, who only gets information about adequately healthy nutrition during pregnancy and lactation.

The amount of fat in newborns is measured through skinfold thickness, ultrasound, and magnetic resonance imaging (MRI).

It is hypothesised that a reduction in arachidonic acid intake and an increase of n-3 LC PUFAs (long chain polyunsaturated fatty acids) via supplements containing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) could lead to less expansive fat tissue development in the first year of life.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: n-3 fatty acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: olive oil | Intervention Type: DIETARY_SUPPLEMENT; Name: n-3 fatty acid; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: olive oil; Assigned to Arm(s): 2
B: Arm Label: Marinol; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Marinol D-40 | Arm Label: Nutrition counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Marinol D-40; Assigned to Arm(s): Marinol
C: Arm Label: Docosahexaenoic Acid (DHA); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA; Assigned to Arm(s): Docosahexaenoic Acid (DHA) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 200 mg/day DHA; Type: PLACEBO_COMPARATOR; Interventions: Drug: Docosahexaenoic acid - 200mg/day, Other: Placebo | Arm Label: 1000 mg/day DHA; Type: EXPERIMENTAL; Interventions: Drug: Docosahexaenoic acid - 800mg/day, Drug: Docosahexaenoic acid - 200mg/day | Intervention Type: DRUG; Name: Docosahexaenoic acid - 800mg/day; Assigned to Arm(s): 1000 mg/day DHA | Intervention Type: DRUG; Name: Docosahexaenoic acid - 200mg/day; Assigned to Arm(s): 1000 mg/day DHA, 200 mg/day DHA | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 200 mg/day DHA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of the Nutritional Fatty Acids During Pregnancy and Lactation for Early Human Adipose Tissue Development
Brief Summary: Pregnant and lactating women receive n-3 fatty acids starting from week 15 of gestation until 4 months post-partum (pp) in comparison to a control group, who only gets information about adequately healthy nutrition during pregnancy and lactation.

The amount of fat in newborns is measured through skinfold thickness, ultrasound, and magnetic resonance imaging (MRI).

It is hypothesised that a reduction in arachidonic acid intake and an increase of n-3 LC PUFAs (long chain polyunsaturated fatty acids) via supplements containing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) could lead to less expansive fat tissue development in the first year of life.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Dietary Supplement: omega 3 fatty acids | Arm Label: 2; Type: OTHER; Interventions: Dietary Supplement: vegetable oil | Intervention Type: DIETARY_SUPPLEMENT; Name: omega 3 fatty acids; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: vegetable oil; Assigned to Arm(s): 2
B: Arm Label: Control; Type: OTHER; Interventions: Other: Control | Arm Label: Oily fish; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Oily fish consumption | Intervention Type: DIETARY_SUPPLEMENT; Name: Oily fish consumption; Assigned to Arm(s): Oily fish | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Arm Label: Marinol; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Marinol D-40 | Arm Label: Nutrition counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Marinol D-40; Assigned to Arm(s): Marinol
D: Arm Label: fish oil; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fish oil | Arm Label: folate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: folate | Arm Label: fish oil + folate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fish oil + folate | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: fish oil; Assigned to Arm(s): fish oil | Intervention Type: DIETARY_SUPPLEMENT; Name: folate; Assigned to Arm(s): folate | Intervention Type: DIETARY_SUPPLEMENT; Name: fish oil + folate; Assigned to Arm(s): fish oil + folate | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of the Nutritional Fatty Acids During Pregnancy and Lactation for Early Human Adipose Tissue Development
Brief Summary: Pregnant and lactating women receive n-3 fatty acids starting from week 15 of gestation until 4 months post-partum (pp) in comparison to a control group, who only gets information about adequately healthy nutrition during pregnancy and lactation.

The amount of fat in newborns is measured through skinfold thickness, ultrasound, and magnetic resonance imaging (MRI).

It is hypothesised that a reduction in arachidonic acid intake and an increase of n-3 LC PUFAs (long chain polyunsaturated fatty acids) via supplements containing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) could lead to less expansive fat tissue development in the first year of life.


Options:
A: Arm Label: exercise; Type: EXPERIMENTAL; Interventions: Behavioral: specific training program | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: standard | Intervention Type: OTHER; Name: standard; Assigned to Arm(s): control | Intervention Type: BEHAVIORAL; Name: specific training program; Assigned to Arm(s): exercise
B: Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise group | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise group; Assigned to Arm(s): Exercise group
C: Arm Label: Marinol; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Marinol D-40 | Arm Label: Nutrition counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Marinol D-40; Assigned to Arm(s): Marinol
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Exercise, and Breastfeeding Intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diet, Exercise, and Breastfeeding Intervention; Assigned to Arm(s): Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of the Nutritional Fatty Acids During Pregnancy and Lactation for Early Human Adipose Tissue Development
Brief Summary: Pregnant and lactating women receive n-3 fatty acids starting from week 15 of gestation until 4 months post-partum (pp) in comparison to a control group, who only gets information about adequately healthy nutrition during pregnancy and lactation.

The amount of fat in newborns is measured through skinfold thickness, ultrasound, and magnetic resonance imaging (MRI).

It is hypothesised that a reduction in arachidonic acid intake and an increase of n-3 LC PUFAs (long chain polyunsaturated fatty acids) via supplements containing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) could lead to less expansive fat tissue development in the first year of life.


Options:
A: Arm Label: Marinol; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Marinol D-40 | Arm Label: Nutrition counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Marinol D-40; Assigned to Arm(s): Marinol
B: Arm Label: Treatment Group; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity | Arm Label: Wait List Group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Physical Activity | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Treatment Group | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Wait List Group
C: Arm Label: Enhanced NFN Home Program; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental | Arm Label: Nurturing Family Network Home Visitation; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Experimental | Intervention Type: BEHAVIORAL; Name: Experimental; Assigned to Arm(s): Enhanced NFN Home Program, Nurturing Family Network Home Visitation
D: Arm Label: Usual Head Start Exposure; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Parents of Preschoolers Series (POPS); Type: EXPERIMENTAL; Interventions: Behavioral: Parents of Preschoolers Series | Arm Label: POPS + Incredible Years Series (IYS); Type: EXPERIMENTAL; Interventions: Behavioral: Parents of Preschoolers Series, Behavioral: Incredible Years Series | Intervention Type: BEHAVIORAL; Name: Parents of Preschoolers Series; Assigned to Arm(s): POPS + Incredible Years Series (IYS), Parents of Preschoolers Series (POPS) | Intervention Type: BEHAVIORAL; Name: Incredible Years Series; Assigned to Arm(s): POPS + Incredible Years Series (IYS)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Longitudinal Diabetes Care: A Randomized Controlled Trial to Prevent Glycemic Relapse
Brief Summary: This purpose of this study is to determine the optimal frequency of maintenance intervention needed to prevent glycemic relapse.


Options:
A: Arm Label: DH-4; Type: ACTIVE_COMPARATOR; Interventions: Other: Proteus Discover | Arm Label: DH-12; Type: ACTIVE_COMPARATOR; Interventions: Other: Proteus Discover | Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Proteus Discover; Assigned to Arm(s): DH-12, DH-4 | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Intervention Type: BEHAVIORAL; Name: Telephonic diabetes care; Assigned to Arm(s): N/A
C: Arm Label: Telephonic; Type: EXPERIMENTAL; Interventions: Behavioral: telephonic | Arm Label: Standard registry; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: telephonic | Intervention Type: BEHAVIORAL; Name: telephonic; Assigned to Arm(s): Standard registry, Telephonic
D: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Device: Telemedicine | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine

Answer: B